April 22, 2024

Global Innovation Summit 2026

Global Innovation Summit 2026

Welcome to the Global Innovation Summit!

The Global Innovation Summit 2026 is your opportunity to kick off your innovation project with international partners, strengthen your business and explore suitable funding opportunities in over 40 countries.

The one-day event will take place on Wednesday, 6 May 2026 at Messe Basel, Switzerland.

Why attend the Global Innovation Summit 2026?

The Global Innovation Summit is a recurring gathering organised in the framework of Eureka the world’s largest network for supporting collaborative innovation.

The 2026 edition is organised by the Swiss Eureka Chair represented by Innosuisse and focuses on innovation in the biotech industry combined with enabling technologies and services like digitalisation, translational research and development, chemistry, manufacturing, control and quality control processes, etc.

It will feature an international public, inspiring keynotes and a strong focus on matchmaking for international projects. With a thousand participants expected, the Summit offers a unique chance to turn your ideas into action on a global scale.

The Global Innovation Summit runs back-to-back with the annual Swiss Biotech Day and aims at linking the Swiss biotech ecosystem with global businesses and science to strengthen international cooperation.

  • 🌍 Explore international collaboration.
  • 🤝 Make meaningful connections for project funding.
  • 🎤 Learn from industry leaders.
  • 💡 Get inspired.
  • 🚀 Stay ahead of the curve.
  • 🎉 Enjoy the experience.
  • ✨ Attend free of charge.

Take the opportunity to connect, exchange ideas and collaborate. Register now!

register now

Our latest News

discover more
Study shows how lymph node architecture affects cancer growth

Study shows how lymph node architecture affects cancer growth

A new study maps the organisation of immune and stromal cells in lymph nodes and shows how loss of this organisation affects prognosis in certain lymphomas Summary Researchers from EMBL Heidelberg, Heinrich Heine University Düsseldorf (HHU), and Düsseldorf University Hospital (UKD) have succeeded for the first time in mapping the organisation of immune and stromal […]

High-throughput testing of drugs on mini-tumors reveals vulnerabilities in meningiomas

High-throughput testing of drugs on mini-tumors reveals vulnerabilities in meningiomas

Meningiomas are the most common brain tumors. Until now, only two methods have generally been considered for treating them: surgery and radiation therapy. A research team in Heidelberg has now developed a potential new approach for effective systemic therapy. Its members from Heidelberg University’s Faculty of Medicine and Heidelberg University Hospital (UKHD) tested the effectiveness […]

Development of a method for improved monitoring of the early stages of bone marrow cancer

Development of a method for improved monitoring of the early stages of bone marrow cancer

An international team, including researchers from Heidelberg University’s Faculty of Medicine and Heidelberg University Hospital, has developed the PANGEA-SMM prognostic tool. This tool makes it possible to determine with greater accuracy than before whether a precancerous condition—known as “smoldering multiple myeloma”—is progressing and thus requires treatment. The free online tool for treatment teams is available […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp